-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating from Analysts at StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating from Analysts at StockNews.com
Analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note issued to investors on Sunday. The brokerage set a "sell" rating on the biotechnology company's stock.
Other analysts have also recently issued research reports about the stock. Stifel Nicolaus cut shares of Genocea Biosciences from a "buy" rating to a "hold" rating in a research report on Friday, April 29th. Robert W. Baird dropped their target price on shares of Genocea Biosciences from $8.00 to $3.00 in a research report on Monday, April 11th. Finally, HC Wainwright cut shares of Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th.
Get Genocea Biosciences alerts:Genocea Biosciences Stock Performance
Shares of Genocea Biosciences stock opened at $0.01 on Friday. The firm has a fifty day moving average of $0.05 and a two-hundred day moving average of $0.60. The stock has a market capitalization of $704,760.00, a price-to-earnings ratio of -0.02 and a beta of 2.26. Genocea Biosciences has a 52 week low of $0.01 and a 52 week high of $2.20. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
Insider Activity
In other news, major shareholder Paul Edward Walker sold 5,931,843 shares of the business's stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the completion of the transaction, the insider now owns 4,445,093 shares of the company's stock, valued at approximately $311,156.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Paul Edward Walker sold 5,931,843 shares of the business's stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the completion of the transaction, the insider now owns 4,445,093 shares of the company's stock, valued at approximately $311,156.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ali Behbahani sold 4,445,093 shares of the business's stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $0.08, for a total transaction of $355,607.44. The disclosure for this sale can be found here. Insiders sold 10,537,612 shares of company stock valued at $781,461 in the last quarter. Company insiders own 1.61% of the company's stock.Hedge Funds Weigh In On Genocea Biosciences
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC increased its stake in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities and Exchange Commission. 59.25% of the stock is owned by institutional investors.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Three Watchlist Stocks to Capitalize on Sector Rotation
- MarketBeat: Week in Review 7/18 – 7/22
- Falling Copper Prices Weigh On Freeport McMoran's Earnings, But Long Term Fundamentals Intact
- Snap Stock Falters As Growth Slows To Record Low
- Lackluster Results Provide An Opportunity In Tractor Supply Company
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
斯托克新闻网的分析师在周日发布给投资者的一份研究报告中开始报道Genocea Biosciences(纳斯达克:GNCA-GET评级)的股票。该经纪公司对这家生物技术公司的股票设定了“卖出”评级。
其他分析师最近也发布了关于该股的研究报告。在4月29日星期五的一份研究报告中,Stifel Nicolaus将Genocea Biosciences的股票评级从“买入”下调至“持有”。在4月11日星期一的一份研究报告中,罗伯特·W·贝尔德将Genocea Biosciences的目标股价从8.00美元下调至3.00美元。最后,在4月29日(星期五)的一份研究报告中,HC Wainwright将Genocea Biosciences的股票评级从“买入”下调至“中性”。
到达Genocea生物科学警报:Genocea Bioscions股票表现
Genocea Biosciences的股票上周五开盘报0.01美元。该公司的50日移动均线切入位在0.05美元,200日移动均线切入位在0.60美元。该股市值为704,760.00美元,市盈率为-0.02,贝塔系数为2.26。Genocea Biosciences的52周低点为0.01美元,52周高位为2.20美元。该公司的负债权益比率为0.24,速动比率为1.35,流动比率为1.35。
内幕活动
在其他新闻方面,大股东保罗·爱德华·沃克在5月24日星期二的一次交易中出售了5931,843股该公司股票。这些股票的平均价格为0.07美元,总价值为415,229.01美元。交易完成后,该内部人士现在拥有该公司4,445,093股股票,价值约311,156.51美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的,可以通过这个链接获得。在其他新闻方面,大股东保罗·爱德华·沃克在5月24日星期二的一次交易中出售了5931,843股该公司股票。这些股票的平均价格为0.07美元,总价值为415,229.01美元。交易完成后,该内部人士现在拥有该公司4,445,093股股票,价值约311,156.51美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的,可以通过这个链接获得。此外,董事阿里巴巴-SW贝赫巴哈尼在5月25日(星期三)的一笔交易中出售了4445,093股该公司股票。这些股票以0.08美元的平均价格出售,总成交金额为355,607.44美元。此次拍卖的披露信息可在此处找到。内部人士在上个季度出售了10,537,612股公司股票,价值781,461美元。公司内部人士持有该公司1.61%的股份。对冲基金参与Genocea Bioscions
一家对冲基金最近增持了Genocea Biosciences股票。据英联邦股权服务公司在最近提交给美国证券交易委员会的文件中称,该公司第四季度将其在Genocea Biosciences,Inc.(纳斯达克代码:GNCA-GET评级)的持股增加了49.4%。该公司持有这家生物技术公司31,981股股票,在此期间又购买了10,576股。截至最近向美国证券交易委员会提交的文件,英联邦股权服务公司拥有Genocea Biosciences公司约0.06%的股份,价值3.7万美元。59.25%的股票由机构投资者持有。
关于Genocea生物科学
(获取评级)
Genocea Biosciences,Inc.是一家生物制药公司,发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS,该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
推荐故事
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- 三只关注名单上的股票将利用行业轮换
- MarketBeat:回顾一周7/18-7/22
- 铜价下跌拖累自由港麦克莫兰的收益,但长期基本面完好无损
- 经济增长放缓至创纪录低点,股市暴跌
- 低迷的业绩为拖拉机供应公司提供了机会
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧